On September 30, 2025 electroCore, Inc. announced that the Belgian national health insurer RIZIV/INAMI has added its gammaCore Sapphire non‑invasive vagus nerve stimulation device to a long‑term reimbursement policy for cluster headache treatment, effective October 1, 2025. The policy covers the device for patients with cluster headaches, providing a formal payment mechanism for the therapy in Belgium’s public health system.
The approval marks a significant expansion of electroCore’s prescription product reach into the European market, offering a new revenue stream beyond the U.S. VA channel. It also signals regulatory confidence in the clinical and cost‑effectiveness of gammaCore, potentially easing entry into other European countries and strengthening the company’s competitive position in the neuromodulation space.
Silvert Medical, electroCore’s Belgian distribution partner, played a key role in securing the reimbursement and will continue to support rollout. Senior Director of Strategic Product Lifecycle Tanja Martin noted that “Securing long‑term reimbursement in Belgium, in the center of Europe, is a major milestone in expanding access to our non‑invasive therapies.”
The decision is expected to broaden patient access to gammaCore in Belgium, enhance the company’s international presence, and lay the groundwork for future reimbursement approvals across Europe, positioning electroCore for sustained growth in its core prescription business.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.